secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096165
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences reports Q2 2024 net loss $21.5M; stops KZR-261 Phase 1, revises PORTOLA data to H1 2025
--------------------------------------------------------------------------------

- Net loss $21.5M ($0.30 per share) vs $24.3M ($0.34) in Q2 2023; cash $164.2M (down from $201.4M Dec 2023).
- Enrollment completed in PORTOLA Phase 2a for autoimmune hepatitis; topline data expected first half 2025 (revised from prior guidance).
- Enrollment stopped in KZR-261 Phase 1 for refractory solid tumors; no objective responses observed, resources redirected to zetomipzomib.
- PALIZADE Phase 2b for lupus nephritis actively enrolling; topline data expected mid-2026.
- R&D expenses down $4.7M to $16.3M vs $21.0M; restructuring charge $1.5M related to office space impairment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024096165/0000950170-24-096165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024096165/kzr-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer